This shared resource supports 2 functions: patient sample repository and specialized flow cytometry. The repository functions of the core include the acquisition of appropriate patient samples, isolation and cryopreservation of mononuclear cells, separation and storage of plasma or serum, maintenance of a database annotating patient samples and distribution of samples to program investigators. We will safeguard patient privacy by ensuring that all samples are de-identified and are assigned coded unique identifying numbers. We will also verify compliance with our internal regulatory policies which stipulate that samples may be obtained and studied only from patients who have signed an IRB approved informed consent document. The flow cytometry functions of the core include multiparameter analysis of heterogeneous samples and high-speed cell sorting to obtain highly purified populations of defined progenitor populations.
The specific aims of this core are listed below: 1. To ensure the maintenance of patient privacy and to verify that informed consent has been obtained for acquisition and study of all samples. 2. To ensure the acquisition of appropriate samples as designated in clinical research protocols carried out by program investigators. 3. To isolate and cryopreserve mononuclear cells and plasma or serum components from patient samples for subsequent study by program investigators. 4. To maintain an annotated database containing pathologic, cytogenetic and molecular information for clinical samples obtained from patients with myeloid leukemias. 5. To ensure that samples are distributed in a timely and equitable fashion to laboratory investigators for experiments proposed in this application. 6. To provide specialized multi-parameter analysis and high-speed cell sorting to obtain highly purified populations for functional and genetic analysis

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA066996-14
Application #
8254472
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2011-04-01
Project End
2013-03-30
Budget Start
2011-04-01
Budget End
2012-03-31
Support Year
14
Fiscal Year
2011
Total Cost
$178,125
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Gooptu, Mahasweta; Kim, Haesook T; Chen, Yi-Bin et al. (2018) Effect of Antihuman T Lymphocyte Globulin on Immune Recovery after Myeloablative Allogeneic Stem Cell Transplantation with Matched Unrelated Donors: Analysis of Immune Reconstitution in a Double-Blind Randomized Controlled Trial. Biol Blood Marrow Transplant 24:2216-2223
Gutierrez-Martinez, Paula; Hogdal, Leah; Nagai, Manavi et al. (2018) Diminished apoptotic priming and ATM signalling confer a survival advantage onto aged haematopoietic stem cells in response to DNA damage. Nat Cell Biol 20:413-421
Nabet, Behnam; Roberts, Justin M; Buckley, Dennis L et al. (2018) The dTAG system for immediate and target-specific protein degradation. Nat Chem Biol 14:431-441
Kleppe, Maria; Koche, Richard; Zou, Lihua et al. (2018) Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms. Cancer Cell 33:29-43.e7
List, Alan; Ebert, Benjamin L; Fenaux, Pierre (2018) A decade of progress in myelodysplastic syndrome with chromosome 5q deletion. Leukemia 32:1493-1499
Ebert, Benjamin L; Krönke, Jan (2018) Inhibition of Casein Kinase 1 Alpha in Acute Myeloid Leukemia. N Engl J Med 379:1873-1874
Sellar, Rob S; Jaiswal, Siddhartha; Ebert, Benjamin L (2018) Predicting progression to AML. Nat Med 24:904-906
Hshieh, Tammy T; Jung, Wooram F; Grande, Laura J et al. (2018) Prevalence of Cognitive Impairment and Association With Survival Among Older Patients With Hematologic Cancers. JAMA Oncol 4:686-693
Patel, Sanjay S; Kuo, Frank C; Gibson, Christopher J et al. (2018) High NPM1-mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML. Blood 131:2816-2825
Montero, Joan; Letai, Antony (2018) Why do BCL-2 inhibitors work and where should we use them in the clinic? Cell Death Differ 25:56-64

Showing the most recent 10 out of 376 publications